Marketed By
Hetero
Pack of
12ml/Vial
Salt Composition
Bevacizumab
Storage
Keep in cold place
Contact for Price
Cizumab 300mg Injection
Delivering To: —
All Substitutes
Indication
Rectal Cancer, Colorectal Cancer, Chemotherapy, Brain tumor
Description
Cizumab 300mg Injection is an anti-cancer medication used in the treatment of several types of cancer, such as colorectal, rectal, non-small cell lung cancer, ovarian, and brain tumors. Its active ingredient is Bevacizumab, a monoclonal antibody that works by inhibiting vascular endothelial growth factor (VEGF). It works by blocking VEGF, which prevents the formation of new blood vessels that supply nutrients and oxygen to tumors.
The medicine slows or stops the growth of cancer cells in the body. A doctor's prescription is highly required while taking the medications. The exact dosage and duration is only recommended by the healthcare professional.
Uses
- Colorectal Cancer
- Rectal Cancer
- Non-small cell lung Cancer
- Ovarian Cancer
- Brain tumor
Side Effects
Every medication has certain side effects. Cizumab 300mg Injection also caused various side effects. Consult the doctor if any of the symptoms persist:
- Numbness in hands or feet
- Weakness and lack of energy
- Diarrhea, nausea, vomiting, abdominal pain
- Constipation
- Loss of appetite
- Weight loss
- Headache
- Vision changes
- Confusion
- Severe allergic reactions
- High Blood pressure
- Delayed wound healing following surgery
- Protein in urine
- Severe infections
- Decrease in counts of white blood cells
- Fever
- Dry skin
- Back pain
How To Use
The doctor prescribed Cizumab 300mg Injection to be administered intravenously (IV) under medical supervision. The medicine should be used under medical supervision to ensure a safe and effective treatment option. Do not skip or miss the dose, as it may decrease the effectiveness of the medication. Consult with the doctor on the missed dose. Do not self-administer as improper use may lead to serious side effects.
How It Works
Colorectal, rectal, ovarian, and some other cancers are formed by vascular endothelial growth factor (VEGF), which is a single protein or growth factor that stimulates the growth of new blood vessels (angiogenesis). Cizumab 300mg Injection blocks the protein called VEGF, which helps cancer grow blood vessels. When the medicine stops VEGF, the tumor receives less blood and oxygen. This slows down or stops the growth and spread of cancer cells in the body.
Safety Advice
Alcohol
UNSAFE
Pregnancy
CONSULT YOUR DOCTOR
Breast Feeding
CONSULT YOUR DOCTOR
Driving
DANGER
Kidney
PRECAUTION
Liver
PRECAUTION
FAQs
Cizumab 300mg Injection is taken by non small cell lung cancer, colorectal cancer, rectal cancer, kidney cancer, ovarian cancer, cervical cancer, and brain tumor by blocking the epidermal growth factor receptor. The medicine stops the growth and progression of cancer cells in the body.
Cizumab 300mg Injection is targeted therapy that directly focuses on the cancer cells to kill them and prevent the body from further growing cancer in the body.
The duration and dosage of Cizumab 300mg Injection depend on the patient's medical history and the prescription of a doctor. Consult the healthcare expert to know the complete information about the medication.
Some patients may experience side effects such as itching, headache, loss of appetite, and many more. Consult the doctor about the symptoms and follow the dosage as recommended by the healthcare expert.
Cizumab 300mg Injection blocks the vascular endothelial growth factor (VEGF), which is responsible for the growth of cancer cells in the body. This helps to slow or stop the growth and spread of tumors by cutting off their blood supply.
References
- McCormack, P. L., & Keam, S. J. (2008). Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs, 68(4), 487-506. https://pubmed.ncbi.nlm.nih.gov/18318567/
- Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., ... & Liang, S. X. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365(26), 2473-2483. https://pubmed.ncbi.nlm.nih.gov/22204724/
- Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007). Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 114(5), 855-859. https://pubmed.ncbi.nlm.nih.gov/17467524/
- Keating, G. M. (2014). Bevacizumab: a review of its use in advanced cancer. Drugs, 74(16), 1891-1925. https://pubmed.ncbi.nlm.nih.gov/25315029/
- Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery, 3(5), 391-400. https://pubmed.ncbi.nlm.nih.gov/15136787/
Ratings And Reviews
4.57/5
7 Ratings
5 Star
71.43%
4 Star
14.29%
3 Star
14.29%
2 Star
0.00%
1 Star
0.00%
Ravi Malhotra
Best purchase I've made
a year ago
Priya Reddy
Quality is outstanding
a year ago
View All Reviews
Related Products
MARKETER DETAILS
Hetero
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.